Market Overview:
The global sex cord gonadal stromal tumor market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of sex cord gonadal stromal tumors, increasing awareness about the disease, and technological advancements in the field of diagnosis and treatment. However, lack of reimbursement for certain treatments and high cost of treatment are some factors that could restrain the growth of this market during the forecast period. Based on type, the global sex cord gonadal stromal tumor market is segmented into diagnosis and treatment. The diagnostic segment is further sub-segmented into imaging techniques (ultrasound scan, computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) scan) and histopathology tests. On the basis of treatment, the market is divided into surgery, radiation therapy, chemotherapy drugs, hormone therapy drugs and other treatments such as targeted therapy or stem cell transplantation therapies . On basis on application ,the global sex cord gonadal stromal tumormarket can be classifiedinto four segments: hospital use , clinic use research centerand other applications .
Product Definition:
A sex cord gonadal stromal tumor is a rare type of tumor that develops in the ovaries or testes. These tumors are made up of cells that normally support the reproductive organs.
Diagnosis:
The global diagnosis market size was valued at USD 1.1 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period.
Treatment:
Sex Cord Gonadal Stromal Tumor Market is a type of cancer that begins in the sex cords or gonads (ovarian and testicular). The most common types are stromal cell tumors of the testis (TST) and ovary.
The disease has an incidence rate of 1-2 per 100,000 people annually. It mostly affects middle-aged men and women due to the rising geriatric population base across the globe.
Application Insights:
The other application segment includes the use of sex cord tumor for research purposes. The growth in this segment can be attributed to increasing adoption of advanced techniques, such as genetic engineering and stem cell transplantation, for treatment of cancer. In addition, a rise in the number of clinical trials using SCTs as a therapy is expected to boost market growth during the forecast period.
For instance, an ongoing phase 3 clinical trial by Genitourinary Tumor Society (GTS) is evaluating whether or not patients with low-risk prostate cancer are good candidates for SCT followed by docetaxel chemotherapy after surgery. This study has been designed to look at outcomes associated with these therapies and see if they are better than those who receive hormone-based therapy alone after their initial diagnosis has been made through biopsy or needle biopsies.
Regional Analysis:
North America dominated the global sex cord gonadal stromal tumor market in 2017. This can be attributed to increasing cases of testicular cancer, rising awareness about early diagnosis, and availability of treatment options. In addition, high incidence rate of other cancers in this region is also driving demand for SCTs from North American countries. For instance, according to the National Cancer Institute (NCI), prostate cancer is the second most commonly diagnosed cause of death among men in U.S., while testicular cancer ranks third most common type there [1].
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing number of patients suffering from SCGNT as well as growing medical tourism industry due to low cost involved procedures coupled with availability of treatments in emerging countries like India and China compared with developed ones like U.S., Canada & European Union (EU).
Growth Factors:
- Increasing incidence of Sex Cord Gonadal Stromal Tumor
- Rising awareness about Sex Cord Gonadal Stromal Tumor among people
- Growing number of research and development activities for Sex Cord Gonadal Stromal Tumor treatment
- Technological advancements in the field of diagnosis and treatment of Sex Cord Gonadal Stromal Tumor
- Availability of government funding for research on Sex Cord Gonadal Stromal Tumor
Scope Of The Report
Report Attributes
Report Details
Report Title
Sex Cord Gonadal Stromal Tumor Market Research Report
By Type
Diagnosis, Treatment
By Application
Hospital Use, Clinic Use, Research Center, Other
By Companies
Abbott, Abcam plc., Affymetrix, Inc., Agilent Technologies, Inc., Beckman Dickinson and Company, Bio SB Inc., BioCurex, BioModa, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cell Signaling Technology, Inc., Clarient, Inc., CooperSurgical Inc., Correlogic Systems, Inc., Danaher Corporation, Epigenomics AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
139
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Sex Cord Gonadal Stromal Tumor Market Report Segments:
The global Sex Cord Gonadal Stromal Tumor market is segmented on the basis of:
Types
Diagnosis, Treatment
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Use, Clinic Use, Research Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott, Abcam plc.
- Affymetrix, Inc.
- Agilent Technologies, Inc.
- Beckman Dickinson and Company
- Bio SB Inc.
- BioCurex
- BioModa, Inc.
- Bio-Rad Laboratories, Inc.
- Boston Scientific Corporation
- Cell Signaling Technology, Inc.
- Clarient, Inc.
- CooperSurgical Inc.
- Correlogic Systems, Inc.
- Danaher Corporation
- Epigenomics AG
Highlights of The Sex Cord Gonadal Stromal Tumor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Diagnosis
- Treatment
- By Application:
- Hospital Use
- Clinic Use
- Research Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sex Cord Gonadal Stromal Tumor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A sex cord tumor is a rare type of cancer that arises from the cells that line the spinal cord. These tumors can grow and spread to other parts of the body, including the brain. Sex cord tumors are most commonly found in men, but they can also occur in women.
Some of the major companies in the sex cord gonadal stromal tumor market are Abbott, Abcam plc., Affymetrix, Inc., Agilent Technologies, Inc., Beckman Dickinson and Company, Bio SB Inc., BioCurex, BioModa, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cell Signaling Technology, Inc., Clarient, Inc., CooperSurgical Inc., Correlogic Systems, Inc., Danaher Corporation, Epigenomics AG.
The sex cord gonadal stromal tumor market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sex Cord Gonadal Stromal Tumor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sex Cord Gonadal Stromal Tumor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sex Cord Gonadal Stromal Tumor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sex Cord Gonadal Stromal Tumor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sex Cord Gonadal Stromal Tumor Market Size & Forecast, 2018-2028
4.5.1 Sex Cord Gonadal Stromal Tumor Market Size and Y-o-Y Growth
4.5.2 Sex Cord Gonadal Stromal Tumor Market Absolute $ Opportunity
Chapter 5 Global Sex Cord Gonadal Stromal Tumor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Sex Cord Gonadal Stromal Tumor Market Size Forecast by Type
5.2.1 Diagnosis
5.2.2 Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Sex Cord Gonadal Stromal Tumor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Sex Cord Gonadal Stromal Tumor Market Size Forecast by Applications
6.2.1 Hospital Use
6.2.2 Clinic Use
6.2.3 Research Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Sex Cord Gonadal Stromal Tumor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Sex Cord Gonadal Stromal Tumor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Sex Cord Gonadal Stromal Tumor Analysis and Forecast
9.1 Introduction
9.2 North America Sex Cord Gonadal Stromal Tumor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Sex Cord Gonadal Stromal Tumor Market Size Forecast by Type
9.6.1 Diagnosis
9.6.2 Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Sex Cord Gonadal Stromal Tumor Market Size Forecast by Applications
9.10.1 Hospital Use
9.10.2 Clinic Use
9.10.3 Research Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Sex Cord Gonadal Stromal Tumor Analysis and Forecast
10.1 Introduction
10.2 Europe Sex Cord Gonadal Stromal Tumor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Sex Cord Gonadal Stromal Tumor Market Size Forecast by Type
10.6.1 Diagnosis
10.6.2 Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Sex Cord Gonadal Stromal Tumor Market Size Forecast by Applications
10.10.1 Hospital Use
10.10.2 Clinic Use
10.10.3 Research Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Sex Cord Gonadal Stromal Tumor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Sex Cord Gonadal Stromal Tumor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Sex Cord Gonadal Stromal Tumor Market Size Forecast by Type
11.6.1 Diagnosis
11.6.2 Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Sex Cord Gonadal Stromal Tumor Market Size Forecast by Applications
11.10.1 Hospital Use
11.10.2 Clinic Use
11.10.3 Research Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Sex Cord Gonadal Stromal Tumor Analysis and Forecast
12.1 Introduction
12.2 Latin America Sex Cord Gonadal Stromal Tumor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Sex Cord Gonadal Stromal Tumor Market Size Forecast by Type
12.6.1 Diagnosis
12.6.2 Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Sex Cord Gonadal Stromal Tumor Market Size Forecast by Applications
12.10.1 Hospital Use
12.10.2 Clinic Use
12.10.3 Research Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Sex Cord Gonadal Stromal Tumor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Sex Cord Gonadal Stromal Tumor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Sex Cord Gonadal Stromal Tumor Market Size Forecast by Type
13.6.1 Diagnosis
13.6.2 Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Sex Cord Gonadal Stromal Tumor Market Size Forecast by Applications
13.10.1 Hospital Use
13.10.2 Clinic Use
13.10.3 Research Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Sex Cord Gonadal Stromal Tumor Market: Competitive Dashboard
14.2 Global Sex Cord Gonadal Stromal Tumor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott, Abcam plc.
14.3.2 Affymetrix, Inc.
14.3.3 Agilent Technologies, Inc.
14.3.4 Beckman Dickinson and Company
14.3.5 Bio SB Inc.
14.3.6 BioCurex
14.3.7 BioModa, Inc.
14.3.8 Bio-Rad Laboratories, Inc.
14.3.9 Boston Scientific Corporation
14.3.10 Cell Signaling Technology, Inc.
14.3.11 Clarient, Inc.
14.3.12 CooperSurgical Inc.
14.3.13 Correlogic Systems, Inc.
14.3.14 Danaher Corporation
14.3.15 Epigenomics AG
